Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Abstract excerpt

Abstract The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunotherapy and Immune Responses
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors